Infinity Pharmaceuticals: Rises on promising data from bladder cancer study
11/02/2021 13:01
** Drugmaker's shares INFI.O jumps 36.2% to $5.38
premarket
** Co says its experimental drug candidate, eganelisib, in
combination with Bristol Myers Squibb Co's BMY.N Opdivo was
well-tolerated and improved overall response rate, disease
control rate, and progression free survival in patients with
advanced bladder cancer (https://refini.tv/2OjNhei)
** Data from the mid-stage study was presented at 2021 ASCO
Genitourinary Cancers Symposium
** Based on strength of data, INFI is planning
registration-enabling study in advanced bladder cancer
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX